ClinicalTrials.gg
RecruitingNCT07310693CLOVERUpdated Dec 30, 2025

External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients

An observational study in Venous Thromboembolism (VTE) and Occult Cancer, sponsored by Infanta Leonor University Hospital. Recruiting at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Infanta Leonor University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Venous Thromboembolism with a site in Spain — 9 open to participants now, 9 under way, none of them phase 3. Venous Thromboembolism · Spain.

Planned enrollment
10th of 16
500 · median 1,225
Started
2025
with 1 other
Observational
17 of 52
9 open now
Registered
51st of 52
by date

Among the 52 studies in Venous Thromboembolism with a site in Spain, this one is the 10th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2025, is one of 17 observational ones, and was the 51st registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

9 of the 52 studies in Venous Thromboembolism with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Venous Thromboembolism with a site in Spain, or all of them as a file.
02

Study summary

This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.

Read the detailed description

This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study combines a retrospective and a prospective cohort.

Retrospective cohort:

Patients aged ≥18 years with objectively confirmed symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) diagnosed between January 1, 2000, and August 31, 2022, in participating hospitals across Spain will be included. Patients from centers involved in the model derivation (Hospital Universitario Infanta Leonor and Hospital Universitario de Fuenlabrada) will be excluded. Cases are defined as patients with a histologically confirmed cancer diagnosis occurring between 1 and 24 months after the index VTE event. Controls are defined as patients without a cancer diagnosis during the same period. All variables required for the CLOVER model (age, D-dimer, systolic blood pressure, ALT, hemoglobin, creatinine, total cholesterol, platelet count, triglycerides, leukocyte count, weight, chronic lung disease, heart rate, sex, and previous VTE recurrence) will be extracted from electronic health records using a standardized data collection form. The CLOVER model will be applied to each patient to assess its discrimination for cancer prediction in the retrospective cohort.

Prospective cohort:

From December 1, 2025, to December 31, 2027, consecutive adult patients with objectively confirmed symptomatic VTE will be recruited in participating hospitals. All patients will undergo a standard clinical evaluation including medical history, physical examination, basic laboratory testing (complete blood count and biochemistry), chest X-ray, and age- and sex-appropriate cancer screening tests according to clinical practice guidelines. The CLOVER score will be calculated at the time of VTE diagnosis using a dedicated web-based tool (CLOVER-Web). Patients will be classified as "low risk" or "high risk" based on the optimal F1-score threshold (0.487), corresponding to a sensitivity of 51%, specificity of 95%, PPV of 46%, and NPV of 96%. All participants will be followed for at least two years to determine whether an occult cancer is diagnosed. Further diagnostic testing for suspected cancer will be performed at the discretion of the treating physician, regardless of CLOVER result.

Model performance and bias assessment:

The external validation will evaluate model discrimination using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the ROC curve (AUC). Additional analyses will assess potential prediction bias across demographic and clinical subgroups (e.g., age, sex, comorbidities). Model calibration and temporal performance will also be reviewed, with predefined procedures for identifying deviations from expected behavior. Weekly reports during the prospective phase will alert investigators to performance drift or potential implementation issues in the web-based tool.

Clinician satisfaction:

A secondary objective is to evaluate clinician satisfaction with the CLOVER-Web tool. An online questionnaire specifically designed for this study will be administered to participating clinicians to assess usability, clarity, and clinical utility.

Ethical considerations:

The study follows the Declaration of Helsinki and Spanish regulations on biomedical research and data protection. Retrospective data collection will request exemption from informed consent due to the use of anonymized clinical information. Prospective participants will provide written or electronic informed consent. All data will be pseudonymized and stored securely.

03

Conditions studied

  • Venous Thromboembolism (VTE)
  • Occult Cancer

Keywords

  • Occult Cancer
  • Venous thromboembolism
  • Machine learning
  • Prediction model
  • External validation
  • CLOVER score
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) with objectively confirmed symptomatic venous thromboembolism (deep vein thrombosis or pulmonary embolism) who are consecutively recruited in participating hospitals in Spain. All participants undergo routine clinical evaluation, laboratory testing, and age- and sex-appropriate cancer screening according to standard practice. The population represents real-world patients with new-onset VTE without known or suspected cancer at baseline.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism).
  • Ability to provide written or electronic .

Exclusion criteria

Exclusion Criteria:

  • Suspicion of cancer during the initial diagnostic evaluation for VTE.
  • Participation in another interventional study that may interfere with outcomes.
  • Inability or refusal to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Prospective VTE Cohort

    Adults with objectively confirmed symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) consecutively enrolled from December 2025 to December 2027 in participating hospitals. All participants will undergo routine clinical evaluation, laboratory testing, and cancer screening according to standard practice. The CLOVER score will be calculated at baseline using the web-based tool (CLOVER-Web).

06

What researchers measure

Primary outcomes

  1. Detection of occult cancer within 24 months

    Proportion of participants with a histologically confirmed diagnosis of occult cancer identified between 1 and 24 months after the index venous thromboembolism (VTE) event. Occult cancer is defined as a new cancer diagnosis not clinically evident at the time of VTE diagnosis

    Time frame: 24 months

07

Study locations

12 of 12 sites recruiting
08

References and documents

Publications

  • Franco-Moreno A, Madronal-Cerezo E, de Ancos-Aracil CL, Farfan-Sedano AI, Munoz-Rivas N, Bascunana Morejon-Giron J, Ruiz-Giardin JM, Alvarez-Rodriguez F, Prada-Alonso J, Gala-Garcia Y, Casado-Suela MA, Bustamante-Fermosel A, Alfaro-Fernandez N, Torres-Macho J; CLOVER Research Group. Development of a Predictive Model of Occult Cancer After a Venous Thromboembolism Event Using Machine Learning: The CLOVER Study. Medicina (Kaunas). 2024 Dec 27;61(1):18. doi: 10.3390/medicina61010018. PubMed 39859000 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be shared, including baseline characteristics, clinical variables, imaging results, and outcomes related to occult cancer detection. Data will be made available to qualified investigators upon reasonable request and after signing a data sharing agreement ensuring confidentiality and appropriate use. IPD will be available beginning 12 months after study completion and will remain accessible for 5 years. Access to IPD will be granted to qualified researchers with a methodologically sound research proposal. Requests must be submitted to the study's coordinating center and will be evaluated by the principal investigators. A data use agreement will be required before any data transfer. Data will be hosted on the HORUS-ML secure research platform (restricted access).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be available beginning 12 months after the completion of the study and will remain accessible for a period of 5 years. Supporting documentation will be provided during the same availability window.

Access criteria: IPD will be available to qualified researchers who submit a methodologically sound research proposal. All requests must be evaluated and approved by the principal investigators. Access will require signing a data use agreement ensuring confidentiality and appropriate use. Data will be shared through the secure HORUS-ML platform.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 36 months is below that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 30, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07310693
Lead sponsor
Infanta Leonor University Hospital
Collaborators
Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor
Responsible party
Anabel Franco Moreno (Specialist in Internal Medicine, Infanta Leonor University Hospital) — Principal investigator
First posted
Dec 30, 2025
Start date
Dec 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 30, 2025

Study contacts

Anabel Franco Moreno, MD, PhD
Contact
afranco278@hotmail.com
+34686102661
Anabel Franco Moreno
Contact
afranco278@hotmail.com
MD, PhD
Anabel Franco-Moreno, MD, PhD
principal investigator · Hospital Universitario Infanta Leonor
Franco-Moreno, MD, PhD
principal investigator · Hospital Universitario Infanta Leonor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion